The last day of June 2017 saw the Supreme Court of Canada (SCC) quash the controversial Promise Doctrine. The issue at hand in AstraZeneca Canada Inc v Apotex Inc was…
Tag: Pharmacueticals
in Access to Medicines, Canada, Cross Border Issues, European Union, IP, IP Reform, Jurisdiction, Patents, Pharmaceutical Drugs, Uncategorized0by Editor
1798
CETA: A Very Reasonable Canadian-esque Compromise on Pharmaceutical Intellectual Property Law Changes
At long last, the Canadian Federal Government and the European Commission announced in October that a political agreement has been reached regarding the much anticipated Comprehensive Economic and Trade Agreement…
in Access to Medicines, Blogs, Canada, European Union, IP, Patents, Pharmaceutical Drugs, Regulatory Policy, Uncategorized, US, US-Canada Relations0by Editor
1513
Time for a Change? Fraser Institute Urges Canada to Strengthen its Pharmaceutical IP Laws
A little over a week ago, the Fraser Institute, a prominent and independent Canadian public policy think tank, released a report calling for a strengthening of intellectual property protection for…
in Canada, European Union, Infringement, IP, Jurisdiction, Patentability, Patents, Pharmaceutical Drugs, Regulatory Policy, Supreme Court of Canada, UK, UK, US, US-Canada Relations0by Editor
1899
Sitting This One Out: SCC Refuses to Clarify “Promise of a Patent” Doctrine
Last month, the Supreme Court of Canada (SCC) denied leave to appeal in the case Eli Lilly Canada Inc v Novopharm Ltd, passing on an opportunity to clarify the controversial…